Subscribe to RSS
DOI: 10.1055/s-2004-834414
Karl F. Haug Verlag, in: MVS Medizinverlage Stuttgart GmbH & Co. KG
L-Carnitin aus ernährungsmedizinischer und ernährungswissenschaftlicher Sicht
Publication History
Publication Date:
19 October 2004 (online)
Zusammenfassung
Der natürliche Stoff L-Carnitin transportiert langkettige Fettsäuren vom Zytosol ins Innere der Mitochondrien, wo sie verbrannt werden. Es ist somit Schlüsselsubstanz für die Energiegewinnung aus Fetten. Doch die Fähigkeiten von L-Carnitin gehen weit über die eines „Fatburners” hinaus. L-Carnitin ist an vielen biochemischen Prozessen im Organismus beteiligt. In konzentrierter Form zugeführt hat L-Carnitin gezeigt, dass es in Schwangerschaft und Stillzeit Mutter und Kind vor Erkrankungen bewahren kann, sich bei Herzerkrankungen günstig auf das Herz auswirkt, die Insulinsensitivität verbessert, die Regeneration der Muskulatur nach Belastung fördert und oxidativen Stress reduziert. Der menschliche Körper kann L-Carnitin aus den Aminosäuren L-Lysin und L-Methionin selbst herstellen. Eine Supplementation von L-Carnitin ist sinnvoll in Phasen eines erhöhten Carnitinbedarfs oder eines Carnitinmangels, wie er zum Beispiel bei Dialysepatienten und sekundär in der Schwangerschaft auftreten kann. Auch bei Ausdauersport und vegetarischer Ernährung finden sich deutlich erniedrigte L-Carnitin-Spiegel.
Abstract
The natural substance L-Carnitine transports long-chain fatty acids from the cytosol to the interior of the mitochondria, were they are burned. Therefore L-Carnitine is the key substance for the generation of energy from fats, but it is much more than a mere “fat burner”. L-Carnitine is involved in many biochemical processes in the organism. If L-Carnitine is administered in a concentrated form, the following effects have been shown: during pregnancy it can protect mother and child from diseases, in the case of heart diseases it has a positive effect on the heart, it improves the insulin sensitivity, it stimulates the regeneration of the muscles after strain, and reduces oxidative stress. The human body itself can produce L-Carnitine from the amino acids L-Lysine and L-Methionine. A supplementation of L-Carnitine makes sense during phases of an increased need for carnitine or in the case of a carnitine deficiency, as it can occur in dialysis patients and secondary during pregnancy. During endurance sport as well as a vegetarian diet there are significantly reduced levels of L-Carnitine.
Schlüsselwörter
L-Carnitin - Fettverbrennung - koronare Herzerkrankung - HIV - Adipositas - Schwangerschaft - Sportmedizin - Anti-Aging
Keywords
L-Carnitine - fat burner - coronary cardiac disease - HIV - adiposity - pregnancy - sports medicine - anti-aging
Literatur
- 01 Ahmad S. et al. . Multicenter trial of L-Carnitine in maintainance of hemodialysis patients II. Clinical and biochemical effects. Kidney Int. 1990; 38 912-8
- 02 Blumenthal H, Borzelleca J F, Filer L J. Gutachten zur GRAS Affirmation für die amerikanische Gesundheitsbehörde FDA. 1993
- 03 Böhles H J. Gutachterliche Stellungnahme betreffend den Nährstoff L-Carnitin. Ulm; Gesellschaft für Ernährungsforschung 1994
- 04 Böhles H. et al. . The effect of preoperative L-carnitine supplementation on myocardial metabolism during aorto-coronary bypass surgery. Z. Kariol.. 1987; 76 (S 5) 14-8
- 05 Bruno G, Acaccionace S, Bonamini M. et al. . Acetyl-L-Carnitine in Alzheimer disease: A Short-Term Study on CSF Neurotransmitters and Neuropeptides. Alzheimer Disease and Associated Disorders. 1995; 9 (3) 128-31
- 06 Cacciatore L. et al. . The therapeutic effect of L-Carnitine in patients with exercise-induced stable angina: a controlled study. Drugs Exp. Clin. Res.. 1991; 17 225-35
- 07 Cherchi A di. et al. . Effects of L-carnitine on exercise tolerance in chronic stable angina: a multicenter, double-blind, randomized, placebo controlled crossover study. Int. J. Clin. Pharmacol. Ther. Toxicol.. 1985; 23 569-72
- 08 Cifone M G, Alesse E, Di Marzio L. et al. . Effect of L-carnitine treatment in vivo on apoptosis and ceramide generation in peripheral blood lymphocytes from AIDS patients. Proceedings of the Association of American Physicians. 1997; 109 (2) 146-53
- 09 Di Marzio L, Moretti S, D'Aló S. Acetyl-L-carnitine administration increases insulin-like growth factor 1 levels in asymptomatic HIV-1-infected subjects: correlation with its suppressive effect on lymphocyte apoptosis and ceramide generation. Clinical immunology: the official journal of the Clinical Immunology Society. 1999; 92 (1) 103-10
- 10 Frösch P. Erfolgreiche Carnitinbehandlung bei Polimyelitis. Ärztewoche 11.5.1994
- 11 Gamberardino M A. et al. .Effects of prolonged L-Carnitine administration on delayed muscle pain and CK release after eccentric effort. University of Chieti Padova, Italy;
- 12 Genger. et al. . Carnitinspiegel während der Schwangerschaft. Carnitine levels in pregnancy. Zeitschrift für Geburtshilfe und Perinatologie. 1988; 192 (3) 134-6
- 13 Gross K I, Wedenkind K J, Kirk C A. Effect of dietary L-Carnitine and chromiumpicolinate on weight loss and composition of obese dogs. J.Animal Sci. 1998; 76 (S 1) 175-
- 14 Gustavsen H S M. Inaugural Dissertation zur Erlangung des Doktorgrades. Physiologisches Institut der tierärztlichen Hochschule Hannover Bischofsholer Damm 15/102, 30173 Hannover; unter der Leitung von Prof. Harmeyer 2000
- 15 Ino T. et al. . Cardiac manifestations in disorders of fat and carnitine metabolism in infancy. J. Am. Coll. Cardiol.. 1988; 11 1301-8
- 16 Jackson G. Combination therapy in angina: a review of combined haemodynamic treatment and the role for combined haemodynamic and cardiac metabolic agents. International journal of clinical practice. 2001; 55 (4) 256-61
- 17 Jewell D E, Toll P W. The effect of carnitine supplementation on body composition of obese-prone cats, Adapted from „obesity”: Weight management in Cats and Dogs. Hill's Pet Nutr. 1998;
- 18 Ji H, Bradley T M, Tremblay G C. Atlantic salmon fed L-Carnitine exhibit altered intermedioary metabolism and reduced tissue lipid but no change in growth rate. J Nutr. 1996; 126 (8) 1937-50
- 19 Kaats G R, Wise J A, Blum K. et al. . The short-term therapeutic efficacy of treating obesity with a plan of improved nutrition and moderate caloric restriction. Curr Ther Res. 1992; 51 261-74
- 20 Krämer W J, Volek J S. et al. .The effects of L-Carnitine supplementation on exercise stress responses in recovery. Muncie Ball, Ind./USA; State University
- 21 Lango R, Smolenski R T, Narkiewicz M, Suchorzewska J, Lysiak-Szydlowska W. Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass. Cardiovascular research. 2001; 51 (1) 21-9
- 22 Lehmann T. Poliomyelitis-Spätfolgen: Klinik und Behandlungsmöglichkeiten. Therapiewoche Schweiz. 1993; 9 (7) 421-4
- 23 Lehmann T. Poliomyelitis-Spätfolgen werden oft unterschätzt. Niedersächsisches Ärtzeblatt. 1994; 67 (5) 14-6
- 24 Lurz R, Fischer R. Carnitin zur Unterstützung der Gewichtsabnahme bei Adipositas. Ärztez Naturheilv. 1998; 39 12-5
- 25 Maggini S, Bänzinger K R, Walter P. L-Carnitine supplementation results in improved recovery after strenous exercise. Ann Nutr. Metab. 2000; 44 75-96
- 26 Mannick E E, Udall J N, Kaiser M. et al. . Nutrition and HIV infection in children. Indian journal of pediatrics. 1996; 63 (5) 615-32
- 27 Marcus U. XIV. Internationale AIDS-Konferenz in Barcelona - Auf der Suche nach Commitment. Homepage des Robert-Koch-Instituts http://www.rki.de/INFEKT/AIDS_STD/AKTUELL/DATA/BCNCONF.PDF
- 28 Migueles S A, Laborico A C, Shupert W L. et al. . HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nature Immunology. 2002; 3 1061-8
- 29 Mintz M. Carnitine in human immunodeficiency virus type 1 infection/acquired immune deficiency syndrome. Journal of child neurology. 1995; 10 (S 2) S40-4
- 30 Moretti S, Alesse E, Di Marzio L. et al. . Effect of L-carnitine on human immunodeficiency virus-1 infection-associated apoptosis: a pilot study. Blood. 1998; 91 (10) 3817-24
- 31 Müller D, Richter T, Seim H. Effects of L-Carnitine supplementation on in vivo oxidation off - (C13) palmitic acid in healthy adults. University of Leipzig, Germany;
- 32 Pettegrew W J, Levine J, McClure R J. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Molecular psychiatry. 2000; 5 (6) 616-32
- 33 Polio e.V. .Zum Stichwort Medikamente. 4. Mitteilungsblatt 7-8 1993
- 34 Salzer. et al. . Alternativen zur Cortisontherapie. Erste klinische Erfahrungen mit einer Carnitin-Betamethason-Kombination zur Stimulation der fetalen Lungenreife. Wiener klinische Wochenschrift. 1983; 95 (20) 724-8
- 35 Scarpini E, Sacilotto G, Baron P. et al. . Effect of acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIV + patients. Journal of the peripheral nervous system. JPNS. 1997; 2 (3) 250-2
- 36 Schoderbeck. et al. . Pregnancy-related changes of carnitine and acylcarnitine concentrations of plasma and erythrocytes. Journal of perinatal medicine. 1995; 23 (6) 477-85
- 37 Spagnoli L G. et al. . Morphometric evidence of the trophic effect of L-Carnitine on human skeletal muscle. Nepphron. 1990; 55 16-23
- 38 Sufeng Z, Zhichian H, Jianping L, Hui S. L-Carnitine's effect on comprehensive weight loss program in obese adolescents. Acta Nutr Sin. 1997; 19 146
- 39 Wohlers W, Legenstein e, Kuzmits R, Lechner S, Dobianer K, Lohninger A. Carnitine substitution in cancer patients receiving chemotherapy. In: Seim H, Löster H (Eds.): Carnitine - Pathochemical basics and clinical applications. Bochum; Ponte Press 1996: 265-6
Korrespondenzadresse
Sven-David Müller
Diätassistent/Diabetesberater DDG, Gesellschaft für Ernährungsmedizin und Diätetik e.V.
Wiss. Direktor: Prof. Dr. med. Helmut Mann
Kurbrunnenstr. 5
52066 Bad Aachen
Email: sdmueller@ernaehrungsmed.de
URL: http://www.ernaehrungsmed.de